A mucosal vaccination approach for herpes simplex virus type 2

Vaccine

Volumn 29, Issue 5, 2011, Pages 1090-1098

  Tirabassi, Rebecca S ^a   Ace, Christopher I ^a   Levchenko, Tatyana ^b   Torchilin, Vladimir P ^b   Selin, Liisa K ^c   Nie, Siwei ^a   Guberski, Dennis L ^a   Yang, Kejian ^a  

^a Biomedical Research Models Inc   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

DNA vaccine; Heterologous prime and boost; HSV 2; Liposome; Mucosal delivery; Mucosal vaccine

Indexed keywords

DNA VACCINE; GLYCOPROTEIN D; HEPATITIS B SURFACE ANTIGEN; LIPOSOME; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ADMINISTRATION, MUCOSAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; TIME FACTORS; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT; VAGINA; VIRAL ENVELOPE PROTEINS;

EID: 78751568013     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.076     Document Type: Article

References (46)

1. Handsfield H.H., Stone K.M., Wasserheit J.N. Prevention agenda for genital herpes. Sex Transm Dis 1999, 26(4):228-231.
2. Lafferty W.E., Coombs R.W., Benedetti J., Critchlow C., Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987, 316(23):1444-1449.
3. Mertz G.J., Benedetti J., Ashley R., Selke S.A., Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992, 116(3):197-202.
4. Wald A., Corey L., Cone R., Hobson A., Davis G., Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997, 99(5):1092-1097.
5. Straus S., Corey L. Herpes simplex viruses. Mandell, Douglas, and Bennett's principles and practice of infectious diseases 2000, 1556-1580. Churchill Livingstone, Philadelphia [etc.]. G.L. Mandell, R.G. Douglas, J.E. Bennett, R. Dolin (Eds.).
6. Kimberlin D.W. Antiviral therapy for cytomegalovirus infections in pediatric patients. Semin Pediatr Infect Dis 2002, 13(1):22-30.
7. Stamm W.E., Handsfield H.H., Rompalo A.M., Ashley R.L., Roberts P.L., Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988, 260(10):1429-1433.
8. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-d-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347(21):1652-1661.
9. Whitley R.J., Kimberlin D.W., Roizman B. Herpes simplex viruses. Clin Infect Dis 1998, 26(3):541-553. quiz 554-545.
10. Ashley R.L., Dalessio J., Burchett S., Brown Z., Berry S., Mohan K., et al. Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. J Clin Invest 1992, 90(2):511-514.
11. Dudley K.L., Bourne N., Milligan G.N. Immune protection against HSV-2 in B-cell-deficient mice. Virology 2000, 270(2):454-463.
12. Mester J.C., Milligan G.N., Bernstein D.I. The immunobiology of herpes simplex virus. Genital and neonatal herpes 1996, 49-91. John Wiley and Sons, Ltd., New York. L.R. Stanberry (Ed.).
13. Milligan G.N., Bernstein D.I. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology 1995, 212(2):481-489.
14. Speck P., Simmons A. Precipitous clearance of herpes simplex virus antigens from the peripheral nervous systems of experimentally infected C57BL/10 mice. J Gen Virol 1998, 79(Pt 3):561-564.
15. Koelle D.M., Posavad C.M., Barnum G.R., Johnson M.L., Frank J.M., Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998, 101(7):1500-1508.
16. Posavad C.M., Koelle D.M., Shaughnessy M.F., Corey L. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci USA 1997, 94(19):10289-10294.
17. Posavad C.M., Koelle D.M., Corey L. Tipping the scales of herpes simplex virus reactivation: the important responses are local. Nat Med 1998, 4(4):381-382.
18. Parr M.B., Parr E.L. Mucosal immunity in the female and male reproductive tracts. Handbook of mucosal immunology 1994, 677-689. Academic Press, San Diego. P.L. Ogra, M.E. Lamm, W. Strober, J.R. McGhee, J. Bienenstock (Eds.).
19. Parr M.B., Parr E.L. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes. J Virol 1998, 72(4):2677-2685.
20. Milligan G.N., Bernstein D.I., Bourne N. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 1998, 160(12):6093-6100.
21. Kuklin N.A., Daheshia M., Chun S., Rouse B.T. Role of mucosal immunity in herpes simplex virus infection. J Immunol 1998, 160(12):5998-6003.
22. Gallichan W.S., Rosenthal K.L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J Infect Dis 1998, 177(5):1155-1161.
23. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(2):148-158.
24. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406(6797):793-798.
25. Robinson H.L., Montefiori D.C., Johnson R.P., Manson K.H., Kalish M.L., Lifson J.D., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999, 5(5):526-534.
26. Yang K., Whalen B.J., Tirabassi R.S., Selin L.K., Levchenko T.S., Torchilin V.P., et al. A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection. J Immunol 2008, 180(9):6159-6167.
27. O'Hagan D.T. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 2001, 1(3):273-286.
28. Alving C.R., Koulchin V., Glenn G.M., Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev 1995, 145:5-31.
29. Bourne N., Milligan G.N., Schleiss M.R., Bernstein D.I., Stanberry L.R. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996, 14(13):1230-1234.
30. Bernstein D.I., Tepe E.R., Mester J.C., Arnold R.L., Stanberry L.R., Higgins T. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection. Vaccine 1999, 17(15-16):1964-1969.
31. Cattamanchi A., Posavad C.M., Wald A., Baine Y., Moses J., Higgins T.J., et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol 2008, 15(11):1638-1643.
32. Posavad C.M., Remington M., Mueller D.E., Zhao L., Magaret A.S., Wald A., et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 2010, 184(6):3250-3259.
33. Pertmer T.M., Roberts T.R., Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 1996, 70(9):6119-6125.
34. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997, 158(5):2278-2284.
35. Parr M.B., Parr E.L. The role of gamma interferon in immune resistance to vaginal infection by herpes simplex virus type 2 in mice. Virology 1999, 258(2):282-294.
36. Milligan G.N., Bernstein D.I. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 1997, 229(1):259-268.
37. Baral R.N., Saha A., Chatterjee S.K., Foon K.A., Krieg A.M., Weiner G.J., et al. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immunol Immunother 2003, 52(5):317-327.
38. Sandler A.D., Chihara H., Kobayashi G., Zhu X., Miller M.A., Scott D.L., et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 2003, 63(2):394-399.
39. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 2008, 9(10):776-788.
40. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin 2008, 4(6):449-452.
41. Domingo C., Gadea I., Pardeiro M., Castilla C., Fernandez S., Fernandez-Clua M.A., et al. Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D. Vaccine 2003, 21(25-26):3565-3574.
42. Bridges P.A., Taylor K.M. The effects of freeze-drying on the stability of liposomes to jet nebulization. J Pharm Pharmacol 2001, 53(3):393-398.
43. Bridges P.A., Taylor K.M. An investigation of some of the factors influencing the jet nebulisation of liposomes. Int J Pharm 2000, 204(1-2):69-79.
44. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002, 20(Suppl. 3):S56-S64.
45. Moynihan J.S., Jones D.H., Farrar G.H., Howard C.R. A novel microencapsulated peptide vaccine against hepatitis B. Vaccine 2001, 19(23-24):3292-3300.
46. Natuk R.J., Cooper D., Guo M., Calderon P., Wright K.J., Nasar F., et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 2006, 80(9):4447-4457.